Frumuzachi Oleg, Mocan Andrei, Rohn Sascha, Gavrilaș Laura
Department of Food Chemistry and Analysis, Institute of Food Technology and Food Chemistry, Technische Universität Berlin, Gustav-Meyer-Allee 25, 13355 Berlin, Germany.
Department of Pharmaceutical Botany, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 23 Gheorghe Marinescu Street, 400337 Cluj-Napoca, Romania.
Nutrients. 2025 Apr 28;17(9):1488. doi: 10.3390/nu17091488.
: Chokeberry ( (Michx.) Elliott) is a (poly)phenol-rich fruit with purported cardiometabolic benefits. However, the evidence from randomized controlled trials (RCTs) remains inconclusive. This systematic review and meta-analysis aimed to assess the effects of chokeberry supplementation on cardiometabolic outcomes, including anthropometric parameters, glycemic control, lipid profile, and blood pressure in adults. : A systematic literature search was conducted in PubMed, Scopus, and Web of Science through January 2025. RCTs investigating chokeberry supplementation (≥2 weeks) in adults (≥18 years) with or without cardiometabolic risk factors were included. A random effects model was used to pool effect sizes, expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs). Heterogeneity was assessed using the statistic, and risk of bias was evaluated with the Cochrane risk of bias 1 (RoB 1) tool. Trial sequential analysis (TSA) was performed to assess the conclusiveness of the evidence. Certainty of evidence was rated using GRADE. : Ten RCTs ( = 666 participants) met the inclusion criteria. Chokeberry supplementation had no significant effects on cardiometabolic outcomes under evaluation. Subgroup analysis suggested that a chokeberry supplementation could reduce total cholesterol and LDL-C in individuals with a baseline total plasma cholesterol <200 mg/dL, and systolic blood pressure with interventions, containing >50 mg/day anthocyanin, while increasing fasting blood glucose in individuals ≤50 years old. Risk of bias was unclear or high in several studies, TSA indicated inconclusive evidence for most outcomes, and the certainty of evidence was rated as very low across all cardiometabolic markers. : Chokeberry supplementation did not significantly improve cardiometabolic outcomes in the general adult population. Limited evidence is given for potential lipid-lowering and blood pressure effects in specific subgroups. However, a high risk of bias accompanies these results. More robust RCTs with standardized interventions and dietary assessments are needed.
黑果腺肋花楸（Aronia melanocarpa (Michx.) Elliott）是一种富含（多）酚的水果，据称对心脏代谢有益。然而，随机对照试验（RCT）的证据仍不明确。本系统评价和荟萃分析旨在评估补充黑果腺肋花楸对心脏代谢指标的影响，包括成年人的人体测量参数、血糖控制、血脂谱和血压。
通过在PubMed、Scopus和Web of Science中进行系统的文献检索，检索截至2025年1月的文献。纳入了在有或没有心脏代谢危险因素的成年人（≥18岁）中研究补充黑果腺肋花楸（≥2周）的随机对照试验。采用随机效应模型汇总效应量，以标准化均数差值（SMD）及其95%置信区间（CI）表示。使用I²统计量评估异质性，并使用Cochrane偏倚风险1（RoB 1）工具评估偏倚风险。进行试验序贯分析（TSA）以评估证据的确定性。使用GRADE对证据的确定性进行评级。
十项随机对照试验（n = 666名参与者）符合纳入标准。补充黑果腺肋花楸对所评估的心脏代谢指标没有显著影响。亚组分析表明，补充黑果腺肋花楸可降低基线总血浆胆固醇<200 mg/dL的个体的总胆固醇和低密度脂蛋白胆固醇（LDL-C），以及干预措施中花青素含量>50 mg/天的个体的收缩压，同时增加≤50岁个体的空腹血糖。在几项研究中，偏倚风险不明确或较高，试验序贯分析表明大多数结果的证据不明确，并且所有心脏代谢标志物的证据确定性均被评为非常低。
补充黑果腺肋花楸并未显著改善一般成年人群的心脏代谢指标。在特定亚组中，有有限的证据表明其具有潜在的降脂和降压作用。然而，这些结果伴随着较高的偏倚风险。需要更多采用标准化干预措施和饮食评估的有力随机对照试验。
